Developing novel therapies to treat vascular leak

Board of Directors

Dr. Niclas Stiernholm  PhD, President and CEO, Trillium Therapeutics

 

Dr. Stiernholm is currently the President & CEO of Trillium Therapeutics Inc. (TTI), an immunotherapy research and development company with a strong focus on cancer stem cells. Dr. Stiernholm has served as the CEO of TTI since its inception in 2003. Under his direction and leadership, TTI raised multiple rounds of venture financing, in-licensed several programs from academic institutions, acquired a private Australian company, and executed significant license agreements with major US biotechnology companies, which generated substantial sublicensing revenues. In 2013, TTI became a publicly traded company through a reverse merger and is currently listed on the TSX. Dr. Stiernholm joined TTI from YM BioSciences where he acted as Executive Vice President and Chief Scientific Officer. While there, he led the company’s in-licensing efforts and built a broad pipeline of clinical oncology products. Dr. Stiernholm started his career as a member of Allelix Biopharmaceuticals' business development office. Dr. Stiernholm completed his Ph.D in Immunology at the University of Toronto.

Dr. Raphael Hofstein  President and CEO, MaRS Innovation

Dr. Hofstein joined MaRS Innovation in 2009 after past positions that include Scientific Director of Biotechnological Applications Ltd.; Manager R&D and Chief of Immunochemistry at the International Genetic Scientific Partnership; Scientific Director of the Israeli office of Ecogen Inc.; Vice President, Business Development for Ecogen in Langhorne, Pa.; and President and CEO of Hadasit, the commercialization company of Hadassah, the largest teaching hospital in Israel. Dr. Hofstein was the founder and served as Chair of Hadasit BioHolding Ltd., a publicly traded holding company (10 startups under management) on the Tel Aviv Stock Exchange (TASE), since 2005. Other directorships held on TASE publicly traded companies include: Bioline RX (drug development); Exalenz (medical devices); and Evogene (agri-bio). Dr. Hofstein is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario as well as a member of the Organizing Committee of the Public Policy Forum (part of the Quebec City Conference). Dr. Hofstein received his PhD and Master of Science degrees in Life Sciences and Chemistry from the Weizmann Institute of Science in Rehovot, Israel.

Michael Young Executive Vice President and CAO, Sunnybrook Health Sciences Centre

Michael is Executive Vice President and Chief Administrative Officer at Sunnybrook Health Sciences Centre, a major academic health science centre in Toronto, Ontario. With over 30 years of health care experience, Michael has worked in both for-profit and not-for-profit organizations; both in the Canadian and U.S. health care systems. In Ontario, he held past positions as Vice-President, Information and Corporate Services and C.F.O. at Sunnybrook Health Science Centre; Vice-President, Finance and CFO at Markham Stouffville Hospital; Director of Financial Services at the Wellesley Hospital; and Vice-President, Finance at the Riverdale Hospital (now BridgePoint Health). Michael’s private sector and U.S. experience was gained as C.F.O. and Chief Medicare Compliance Officer for the U.S. operation of Dynacare Laboratories (a $300M medical laboratory NASDQ company); Chief Operating Officer of a privately owned diversified holding company; Regional Vice-President for the Canadian operations of Gentiva Health Services (a $1.5B NASDQ home health care company), where he was responsible of full Canadian subsidiary operations; and Managing Director, Bayshore HealthCare (a division of Bayshore Health Group), where he conceived and orchestrated the purchase of and subsequent integration of Bayshore and Gentiva. Michael is a graduate of the University of Toronto. He articled with Ernst and Young, Chartered Accountants and received his CA (now CPA) designation in 1984. He is currently on the boards of CImTeC (Centre for Imaging Technology Commercialization) and CPSR (Canadian Partnership for Stroke Recovery) and is a past Board Member and Chair of the Finance Committee of Markham Stouffville Hospital Foundation and past Chair of Booth Centennial Hospital Linen Services.

All contents Copyright © 2017, Vasomune Inc. All Rights Reserved